Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 114 of 1,261
  1. US 11999720

    Pyrazolylacylpyrazoline compounds and method for treating pain

    United States Government as represented by the Department of Veterans Affairs Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  2. US 11998528

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  3. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  4. US 12000839

    Methods for characterizing disulfide bonds

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  5. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  6. US 11999747

    Furoquinolinediones as inhibitors of TDP2

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  7. US 12000829

    Selection of patients for combination therapy

    Syndax Pharmaceuticals, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  8. US 11999750

    Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

    DENALI THERAPEUTICS INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  9. US 11999778

    VH4 antibodies and compositions comprising the same

    The Board of Regents of the University of Texas System Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  10. US 11999796

    Anti-CD70 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  11. US 11998635

    Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

    Northwestern University Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  12. US 11998552

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  13. US 11998639

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    AXSOME MALTA LTD. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  14. US 11999799

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  15. US 11998604

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  16. US 11999731

    EGFR dimer disruptors and use of the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  17. US 11998520

    Methods for decreasing injuries associated with intraoperative hypotension

    United States Government as represented by the Department of Veterans Affairs Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  18. US 11999748

    Exatecan derivatives, linker-payloads, and conjugates and thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  19. US 11999971

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  20. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    DESIGNED CELLS CO., LTD. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  21. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    TONIX PHARMA LIMITED Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  22. US 11999753

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  23. US 11998557

    Halogenated psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  24. US 11998606

    Compounds and methods for selective proteolysis of glucocorticoid receptors

    The Board of Regents of the University of Texas System Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.